about
Towards tumor immunodiagnosticsUpdate on the challenges and recent advances in cancer immunotherapySuppression, subversion and escape: the role of regulatory T cells in cancer progressionModification of the tumor microenvironment as a novel target of renal cell carcinoma therapeuticsHPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancerAntitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice.Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients.Interplay between DNA repair and inflammation, and the link to cancerRadiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-545 in Lewis lung carcinoma cellsDiscovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by ChemoradiotherapyAntigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regressionThe role of inflammatory cells in fostering pancreatic cancer cell growth and invasionA HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft modelSialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells.Cancer vaccines: Looking to the future.Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammationEffects of conventional therapeutic interventions on the number and function of regulatory T cells.S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3.Basic principles of tumor-associated regulatory T cell biology.Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.The tumor microenvironment: a pitch for multiple players.Functional dynamics of Foxp3⁺ regulatory T cells in mice and humans.Overcoming tumor-mediated immunosuppression.ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.Frequently Increased but Functionally Impaired CD4+CD25+ Regulatory T Cells in Patients with Oral Lichen Planus.Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.Influence of tumors on protective anti-tumor immunity and the effects of irradiation.Inflammatory microenvironment in the initiation and progression of bladder cancer.Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients.Oncology in 2012: from personalized medicine to precision medicine.
P2860
Q26738691-4F94EC3E-2D19-4DA7-A3BA-B121A612DFFBQ27014693-DFCC8112-D54E-4890-9DF8-87D5F580082BQ27026151-7DE4F236-DEFF-49CB-97DD-3705C7BF45AFQ28393614-787337A8-E362-4FB0-B88B-3312F2801272Q30538743-27A7C974-08EF-4A9F-96BF-79DABED258A7Q33616070-F28BED70-6896-44C6-9758-4AA2DCB22E34Q33769458-1B3BB992-91CA-48C4-9706-D4F0CCF3AF15Q34003592-068BAC8C-C8AA-419E-8698-FEBEC96E503DQ34083746-40435C24-E4ED-465C-A5A8-0DDC28F9D90BQ34989590-7CEC0151-2CED-421A-9F3B-DAFE14CE3C18Q35632080-203769EB-1D32-43E8-9182-B72EB703D3F5Q35857352-E7548B53-F5F6-4751-B01D-36E5D42903A2Q36060263-AB77FE3B-12C7-4B8C-AAAA-3344F14AC4E2Q36202213-EA8DD085-1A9F-4DB3-BBCC-CDB7FE4D050FQ36729501-BB97299C-F27E-4196-AAAC-F92509ED8E6AQ36742670-22862D7A-A820-434E-B673-696FE2673B0EQ36866158-5A66F1FA-E40B-4377-8C36-CAC36CE1BF09Q37259195-9DDF870F-EDA2-4B5D-8E98-9DA0481CB32FQ37390970-CEF83B2E-CFCF-450C-982E-86DA42D299ECQ37706508-B6B0D219-6B6A-46A5-A93F-6E77A6DBF482Q38045603-0DFE510C-BFCC-4394-AB1E-CB285A950C7FQ38082845-2D297BA3-7EEB-4AD9-8446-96FE2E426A5FQ38101567-65B9F7D6-7C5E-4125-8A86-8DF40994CA06Q38202990-447993CA-D541-4A91-8AAD-78AE70F96ECEQ38262255-EF3CC2A6-31D0-4458-8C70-F2B831C50131Q38413705-6548F921-01D1-472F-8812-00A82A9043DAQ38741294-2278EA36-BDAC-4CB4-AC74-DC7AA35A54B7Q39829102-2BE3B9AB-28C3-4FE3-B0DA-0419F7B71D56Q41293978-786E3CA2-ADAE-4192-A1A3-E2B8B9E3E114Q42945799-E5C43025-2113-42DF-95A3-20DA1458862DQ46779353-154B2D7D-DB61-4348-B716-9E70D603AD66Q48219547-12D0F993-BEEF-4629-8567-1DBA7F14E2D5Q49163652-76C143BA-2DB3-4171-A76D-B113237B6B1AQ54469674-52861BF6-7CE0-4676-933A-EE3F3D07B5BE
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting regulatory T cells.
@en
Targeting regulatory T cells.
@nl
type
label
Targeting regulatory T cells.
@en
Targeting regulatory T cells.
@nl
prefLabel
Targeting regulatory T cells.
@en
Targeting regulatory T cells.
@nl
P2093
P2860
P1433
P1476
Targeting regulatory T cells.
@en
P2093
Christine Ménétrier-Caux
Christophe Caux
Julien Faget
Manuarii Manuel
Tyler Curiel
Weiping Zou
P2860
P2888
P356
10.1007/S11523-012-0208-Y
P577
2012-02-12T00:00:00Z